Skip to main content

Table 5 MTHFR A1298C and breast cancer survival

From: Association of MTHFR gene polymorphisms with breast cancer survival

 

Person-years1

# events2

HR (95% CI)3

p-value

A1298C genotype (n = 198)

    

   A/A

  

1

 

   A/C or C/C

873

46

2.05 (1.05–4.00)

0.03

ER-negative (n = 84)

    

   A/A

  

1

 

   A/C or C/C

352

29

2.70 (1.17–6.23)

0.02

ER-positive (n = 114)

    

   A/A

  

1

 

   A/C or C/C

521

17

1.39 (0.43–4.48)

0.58

African-American (n = 121)

    

   A/A

  

1

 

   A/C or C/C

520

29

1.57 (0.70–3.56)

0.28

Caucasian (n = 77)

    

   A/A

  

1

 

   A/C or C/C

352

17

6.28 (1.25–31.7)

0.03

No Chemotherapy (n = 81)

    

   A/A

  

1

 

   A/C or C/C

394

13

7.50 (1.49–37.7)

0.01

Chemotherapy (n = 117)

    

   A/A

  

1

 

   A/C or C/C

479

33

1.62 (0.76–3.46)

0.21

  1. 1 Time at risk in person-years. 2 Number of deaths due to breast cancer. 3 Cox Proportional-Hazards regression with adjustments for age at diagnosis, race, C677T, BMI, estrogen receptor, TNM stage, and chemotherapy.